Dupilumab: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Dupilumab appears in the FDA drug-label database. Marketed as Dupixent.
- Drug class
- Interleukin-4 Receptor alpha Antagonist (FDA established pharmacologic class)
- Mechanism of action
- Interleukin 4 Receptor alpha Antagonists (as stated on the FDA label)
FDA-approved use
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmona…
Phase breakdown
Conditions being studied
Recruiting trials involving Dupilumab
- A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
- A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- DETACT sEvere asThmAtiC paTients - a Pilot Study
- DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
- Ethnic Differences in Mechanisms of Action of Dupilumab
- Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
- Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
- Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
- Molecular Signatures in Inflammatory Skin Disease
- Molecular Signatures of Cutaneous Dupilumab Response
- Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
- Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
- Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
- Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
- Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
- Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
- The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
- Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Common questions
Is Dupilumab FDA-approved?
Yes, marketed as Dupixent.
How many recruiting trials involve Dupilumab?
22 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.